Who owns Celularity Inc.?
The parent company, the largest shareholders that report their holdings, the funds that own Celularity Inc. and what its insiders traded, each from the filing that states it.
The short answer
Celularity Inc. is a listed company: its shares trade on Nasdaq, so it is owned by its shareholders.
33 institutional investors that report to the SEC on Form 13F held 6.6% of its shares on Sep 30, 2026.
The largest of them was C V Starr & Co Inc with 2.35%, followed by Vanguard Capital Management LLC (1.99%) and Geode Capital Management, LLC (0.52%).
6 mutual funds held 2.4% of the company in their latest reports (the newest of Jun 30, 2026); the largest position was Vanguard Total Stock Market Index Fund's.
Newest figure: Sep 30, 2026.
Holdings reported on SEC Form 13F for the quarter ended Sep 30, 2026: 33 holders, 6.6% of the shares together.
| # | Holder | Of the shares | Value | Shares | Change in the quarter |
|---|---|---|---|---|---|
| 1 | C V Starr & Co Inc | 2.35% | $1 M | 764,069 | 0.0% |
| 2 | Vanguard Capital Management LLC | 1.99% | $1 M | 646,444 | +4.1% |
| 3 | Geode Capital Management, LLC | 0.52% | $0 M | 167,150 | 0.0% |
| 4 | Vanguard Fiduciary Trust Co | 0.37% | $0 M | 121,516 | +52.1% |
| 5 | UBS Group AG | 0.25% | $0 M | 80,075 | +4666.4% |
| 6 | BlackRock, Inc. | 0.24% | $0 M | 76,359 | 0.0% |
| 7 | State Street Corp | 0.18% | $0 M | 57,830 | 0.0% |
| 8 | Northern Trust Corp | 0.15% | $0 M | 49,874 | +12.9% |
| 9 | Biltmore Family Office, LLC | 0.11% | $0 M | 35,000 | 0.0% |
| 10 | HB Wealth Management, LLC | 0.10% | $0 M | 31,915 | 0.0% |
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Filings read up to Nov 17, 2026; the quarter is still being filed (99% of last quarter's holders so far). People who hold shares in their own name, such as founders, are not in 13F reports
How ownership moved#
Institutions held 6.6% of Celularity Inc. at Sep 30, 2026, down 0.16 points from Jun 30, 2026; 6 fewer institutions.
| Quarter end | Institutions | Share of the company | Shares bought | Shares sold | Positions opened | Positions closed |
|---|---|---|---|---|---|---|
| Sep 30, 2026(still being filed) | 33 | 6.6% | 196,211 | 13,500 | 3 | 10 |
| Jun 30, 2026 | 39 | 6.8% | 206,082 | 86,417 | 4 | — |
| Mar 31, 2026 | 38 | 7.5% | — | — | — | — |
| Dec 31, 2025 | 36 | 7.7% | — | — | — | — |
| Sep 30, 2025 | 37 | 8.6% | — | — | — | — |
| Jun 30, 2025 | 32 | 7.4% | — | — | — | — |
| Mar 31, 2025 | 28 | 8.3% | — | — | — | — |
| Dec 31, 2024 | 30 | 8.2% | — | — | — | — |
| Sep 30, 2024 | 26 | 4.4% | — | — | — | — |
| Jun 30, 2024 | 26 | 4.3% | — | — | — | — |
| Mar 31, 2024 | 27 | 3.7% | — | — | — | — |
Bought most, quarter to Sep 30, 2026
- UBS Group AG+78,395
- Vanguard Fiduciary Trust Co+41,642
- Vanguard Capital Management LLC+25,339
- Northern Trust Corp+5,711
Sold most
- Jane Street Group, LLC−11,310
- Tower Research Capital LLC (TRC)−1,788
- SBI Securities Co., Ltd.−402
New positions (shares held)
- Sky Investment Group LLC29,920
- Mercer Global Advisors Inc /adv15,200
- Barclays PLC4
Insiders' open-market purchases (up) and sales (down), by quarter
Source: SEC Form 13F data sets and Forms 4 and 5. Institutions report three months after each quarter; a quarter's purchases and sales add up each institution's change since its report for the quarter before. Insiders' trades count open-market purchases and sales only, in the company's reporting currency. 8 mutual funds and ETFs hold Celularity Inc. in their latest reports: 0 new, 4 adding, 2 cutting.
6 funds held 2.4% of the company in their latest reports. Fund holdings are part of what their managers report on Form 13F, so do not add the two.
| Fund | Manager | Country | Of the company | Value | Report of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | The Vanguard Group, Inc. | 🇺🇸 | 1.40% | $0 M | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | Fidelity Management & Research Company LLC | 🇺🇸 | 0.32% | $0 M | May 31, 2026 |
| Vanguard Extended Market Index Fund | The Vanguard Group, Inc. | 🇺🇸 | 0.51% | $0 M | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | Fidelity Management & Research Company LLC | 🇺🇸 | 0.07% | $0 M | May 31, 2026 |
| Fidelity Total Market Index Fund | Fidelity Management & Research Company LLC | 🇺🇸 | 0.06% | $0 M | May 31, 2026 |
Source: Fund portfolios filed with regulators (SEC Form N-PORT and others) · as of Jun 30, 2026
Questions and answers#
Who owns Celularity Inc.?
Celularity Inc. is a listed company: its shares trade on Nasdaq, so it is owned by its shareholders. 33 institutional investors that report to the SEC on Form 13F held 6.6% of its shares on Sep 30, 2026. The largest of them was C V Starr & Co Inc with 2.35%, followed by Vanguard Capital Management LLC (1.99%) and Geode Capital Management, LLC (0.52%).
Who is the largest shareholder of Celularity Inc.?
Among investors that file SEC Form 13F, C V Starr & Co Inc was the largest on Sep 30, 2026, with 2.35% of the shares. Founders, executives and other people who hold shares in their own name report them on SEC Forms 3, 4 and 5 and in the proxy statement, not on Form 13F, so they are not in this ranking.
How much of Celularity Inc. do institutional investors own?
33 institutional investors that report to the SEC on Form 13F held 6.6% of its shares on Sep 30, 2026.
Which mutual funds own Celularity Inc.?
6 mutual funds held 2.4% of the company in their latest reports (the newest of Jun 30, 2026); the largest position was Vanguard Total Stock Market Index Fund's. Funds' holdings are part of what their managers report on Form 13F, so the two shares overlap.
Sources#
Every figure on this page comes from these, with the date shown next to it.
- SEC Form 13F holdings reports
- Fund portfolios filed with regulators (SEC Form N-PORT, Brazil CVM, Sweden Finansinspektionen, Indian fund houses)
More about Celularity Inc.#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M